Prognostic significance of pretreatment albumin-bilirubin (ALBI) grade and platelet-albumin-bilirubin (PALBI) grade in patients with small cell lung cancer.

Journal

Scientific reports

ISSN: 2045-2322

Titre abrégé: Sci Rep

Pays: England

ID NLM: 101563288

Informations de publication

Date de publication:
16 Jan 2024

Historique:

received: 24 12 2022

accepted: 04 01 2024

medline: 17 1 2024

pubmed: 17 1 2024

entrez: 16 1 2024

Statut: epublish

Résumé

Small cell lung cancer (SCLC) is a common cancer among the world's lung cancers. Despite advances in diagnosis and treatment, the prognosis is still poor. There is no effective biomarker other than stage in daily practice. However, in daily practice, patients may have different features and survival times even though they have the same stage. Previously, albumin-bilirubin (ALBI) grade, platelet-albumin-bilirubin (PALBI) grade were used to determine the prognosis of acute-chronic liver failure and acute upper gastrointestinal bleeding in liver cirrhosis. In subsequent studies, they were found to be associated with prognosis in hepatocellular carcinoma (HCC) and other solid cancers. However, the prognostic relationship between ALBI grade, PALBI grade, and SCLC is unknown. Therefore, we conducted this study to examine the relationship between ALBI grade and PALBI grade and prognosis in SCLC patients. Data of 138 patients with advanced SCLC at diagnosis between 2009 and 2020 were analyzed retrospectively. The results of the multivariate analysis were as follows: ALBI grade 1 vs 2, hazard ratio (HR) = 1.608, p = 0.002 for OS and HR = 1.575, p = 0.002 for PFS; ALBI grade 1 vs 3, HR = 2.035, p < 0.001 for OS and HR = 2.675, p < 0.001 for PFS; PALBI grade 1 vs 2, HR = 1.302, p = 0.006 for OS and HR = 1.674, p = 0.002 for PFS; and PALBI grade 1 vs 3, HR = 1.725, p < 0.001 for OS and HR = 2.675, p < 0.001 for PFS. In conclusion, the ALBI and PALBI grades were determined to be associated with the prognosis of SCLC, and they can be used as easy, inexpensive, and practical markers in determining the follow-up treatment and prognosis of SCLC patients.

Identifiants

DOI: 10.1038/s41598-024-51375-2 PMID: 38228667

pubmed: 38228667

doi: 10.1038/s41598-024-51375-2

pii: 10.1038/s41598-024-51375-2

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

1371

Informations de copyright

Références

Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).

doi: 10.3322/caac.21660 pubmed: 33538338

Hiddinga, B. I., Raskin, J., Janssens, A., Pauwels, P. V. & Meerbeeck, J. P. Recent developments in the treatment of small cell lung cancer. Eur. Respir. Rev. 30(161), 210079. https://doi.org/10.1183/16000617.0079-2021 (2021).

doi: 10.1183/16000617.0079-2021 pubmed: 34261744 pmcid: 9488550

Park, M. R. et al. Progression-free survival: An important prognostic marker for long-term survival of small cell lung cancer. Tuberc. Respir. Dis. (Seoul) 76(5), 218–225 (2014).

doi: 10.4046/trd.2014.76.5.218 pubmed: 24920948

Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33(6), 550–558 (2015).

doi: 10.1200/JCO.2014.57.9151 pubmed: 25512453

Liu, P. H. et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J. Gastroenterol. Hepatol. 32(4), 879–886 (2017).

doi: 10.1111/jgh.13608 pubmed: 27696519

Ju, M. et al. The albumin–bilirubin score is a prognostic factor for gastric cancer patients who receive curative treatment. Anticancer Res. 42(8), 3929–3935 (2022).

doi: 10.21873/anticanres.15887 pubmed: 35896262

Imamura, T. et al. Clinical significance of preoperative albumin-bilirubin grade in pancreatic cancer. Ann. Surg. Oncol. 28(11), 6223–6235 (2021).

doi: 10.1245/s10434-021-09593-9 pubmed: 33486645

Lee, H. G. et al. Preoperative albumin–bilirubin score as a prognostic indicator in patients with stage III colon cancer. Sci. Rep. 12(1), 14910. https://doi.org/10.1038/s41598-022-19329-8 (2022).

doi: 10.1038/s41598-022-19329-8 pubmed: 36050367 pmcid: 9437055

Wang, Y. et al. New insights into small-cell lung cancer development and therapy. Cell Biol. Int. 44(8), 1564–1576 (2020).

doi: 10.1002/cbin.11359 pubmed: 32281704 pmcid: 7496722

Zitvogel, L., Pietrocola, F. & Kroemer, G. Nutrition, inflammation and cancer. Nat. Immunol. 18(8), 843–850 (2017).

doi: 10.1038/ni.3754 pubmed: 28722707

McGovern, J., Dolan, R. D., Skipworth, R. J., Laird, B. J. & McMillan, D. C. Cancer cachexia: A nutritional or a systemic inflammatory syndrome?. Br. J. Cancer 127(3), 379–382 (2022).

doi: 10.1038/s41416-022-01826-2 pubmed: 35523879 pmcid: 9073809

Abolhassani, H., Honarvar, N. M., Mosby, T. T. & Mahmoudi, M. Nutrition, immunity, and cancers. In Cancer Immunology 2nd edn (ed. Rezai, N.) 395–405 (Springer, 2015).

doi: 10.1007/978-3-662-44006-3_20

Gupta, D. & Lis, C. G. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr. J. 9, 69. https://doi.org/10.1186/1475-2891-9-69 (2010).

doi: 10.1186/1475-2891-9-69 pubmed: 21176210 pmcid: 3019132

Inoguchi, T., Nohara, Y., Nojiri, C. & Nakashima, N. Association of serum bilirubin levels with risk of cancer development and total death. Sci. Rep. 11(1), 13224. https://doi.org/10.1038/s41598-021-92442-2 (2021).

doi: 10.1038/s41598-021-92442-2 pubmed: 34168201 pmcid: 8225648

Palacios-Acedo, A. L. et al. Platelets, thrombo-inflammation, and cancer: Collaborating with the enemy. Front. Immunol. 10, 1805. https://doi.org/10.3389/fimmu.2019.01805 (2019).

doi: 10.3389/fimmu.2019.01805 pubmed: 31417569 pmcid: 6684752

Wang, Y. et al. Albumin-bilirubin grade as a novel predictor of survival in advanced extrahepatic cholangiocarcinoma. Gastroenterol. Res. Pract. 2018, 8902146. https://doi.org/10.1155/2018/8902146 (2018).

doi: 10.1155/2018/8902146 pubmed: 30622562 pmcid: 6304808

Kinoshita, F. et al. Prognostic impact of albumin–bilirubin (ALBI) grade on non-small lung cell carcinoma: A propensity-score matched analysis. Anticancer Res. 41(3), 1621–1628 (2021).

doi: 10.21873/anticanres.14924 pubmed: 33788758

Takada, K. et al. Assessment of the albumin–bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy. ESMO Open 7(1), 100348. https://doi.org/10.1016/j.esmoop.2021.100348 (2022).

doi: 10.1016/j.esmoop.2021.100348 pubmed: 34942439

Matsukane, R. et al. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Sci. Rep. 11(1), 15057. https://doi.org/10.1038/s41598-021-94336-9 (2021).

doi: 10.1038/s41598-021-94336-9 pubmed: 34301991 pmcid: 8302741